Department of Biomedicine, Institute of Anatomy, University Hospital Basel, University of Basel, Basel, Switzerland.
EBMT Activity Survey Office, Division of Hematology, University Hospital Basel, University of Basel, Basel, Switzerland.
Tissue Eng Part A. 2021 Mar;27(5-6):336-350. doi: 10.1089/ten.TEA.2020.0092. Epub 2020 Sep 18.
This report describes activity in Europe for the years 2016 and 2017 in the area of cellular and tissue-engineered therapies, excluding hematopoietic stem cell treatments for the reconstitution of hematopoiesis. It is the eighth of its kind and is supported by five established scientific organizations. In 2016 and 2017, a combined 234 teams from 29 countries responded to the cellular and engineered tissue therapy survey; 227 teams reported treating 8236 patients in these 2 years. Indications were categorized in (40%; predominantly prevention or treatment of graft vs. host disease and hematopoietic graft enhancement), disorders (29%), disorders (6%), disorders (4%), disorders (<1%), as well as disorders (20%), which were not assigned to the previous indications. The predominantly used cells were autologous (61%). The majority of autologous cells were used to treat (44%) disorders, whereas allogeneic cells were mainly used for (78%). The reported cell types were mesenchymal stem/stromal cells (MSCs) (56%), hematopoietic cells (21%), keratinocytes (7%), chondrocytes (6%) dermal fibroblasts (4%), dendritic cells (2%), and other cell types (4%). Cells were expanded in 62% of the treatments, sorted in 11% of the cases, and rarely transduced (2%). The processing of cells was outsourced to external facilities in 30% of the cases. Cells were delivered predominantly intravenously or intra-arterially [47%], as suspension [36%], or using a membrane/scaffold (16%). The data are compared with those from previous years to identify trends in a rapidly evolving field. In this edition, the report includes a critical discussion of data collected in the space of orthopedics and the use of MSCs.
本报告描述了 2016 年和 2017 年在细胞和组织工程治疗领域在欧洲开展的活动，不包括造血干细胞治疗以重建造血。这是第八次报告，得到了五个成熟科学组织的支持。在 2016 年和 2017 年，来自 29 个国家的 234 个团队对细胞和工程组织治疗调查做出了回应；227 个团队报告在这两年中治疗了 8236 名患者。这些适应症被归类为（40%；主要用于预防或治疗移植物抗宿主病和造血移植物增强）、（29%）、（6%）、（4%）、（<1%）以及（20%）未分配到先前适应症的病症。主要使用的细胞是自体的（61%）。大多数自体细胞用于治疗（44%）病症，而异基因细胞主要用于（78%）。报告的细胞类型为间充质干细胞/基质细胞（MSCs）（56%）、造血细胞（21%）、角质细胞（7%）、软骨细胞（6%）、真皮成纤维细胞（4%）、树突细胞（2%）和其他细胞类型（4%）。在 62%的治疗中对细胞进行了扩增，在 11%的情况下对细胞进行了分类，很少进行转导（2%）。在 30%的情况下，将细胞的处理外包给外部设施。细胞主要通过静脉内或动脉内途径[47%]、作为悬浮液[36%]或使用膜/支架（16%）进行输送。本报告将这些数据与前几年的数据进行比较，以确定在一个快速发展的领域中的趋势。在本版中，报告包括对骨科领域和 MSCs 使用所收集数据的批判性讨论。
